Previous 10 | Next 10 |
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 129 weeks of public selections as part of this ongoing live forward-testing. ...
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in ...
Foamix Pharmaceuticals ( FOMX ) announced that the FDA had accepted its application for review of its topical foam drug FMX103 to treat patients with moderate-to-severe papulopustular rosacea in adults. This opens up the opportunity for the biotech to possibly receive approval for this l...
Foamix Pharmaceuticals (NASDAQ: FOMX ) inks an agreement with ASM Aerosol-Service for the manufacture and supply of AMZEEQ (minocycline) topical foam, 4%, approved by the FDA last week for acne vulgaris, and FMX103 (minocycline) topical foam, 1.5% for the potential treatment of papulopus...
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a long term contract manufacturing and su...
Foamix Pharmaceuticals (NASDAQ: FOMX ), together with licensee LEO Pharma A/S, has settled patent infringement litigation with an affiliate of Teva Pharmaceutical Industries (NYSE: TEVA ) regarding topical rosacea med Finacea Foam. Financial details remain confidential. More news on...
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that, together with LEO Pharma A/S (“LEO Pharma”) it...
AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or t...
AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or t...
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announc...
News, Short Squeeze, Breakout and More Instantly...
Foamix Pharmaceuticals Ltd. Company Name:
FOMX Stock Symbol:
NASDAQ Market:
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address ...
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address ...
REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and...